130 related articles for article (PubMed ID: 33813382)
1. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
[TBL] [Abstract][Full Text] [Related]
2. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
3. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
[TBL] [Abstract][Full Text] [Related]
5. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
6. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
7. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
8. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
[TBL] [Abstract][Full Text] [Related]
9. Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J; Murata T; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Shimoya K; Nomura T; Kurebayashi J; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2475-2479. PubMed ID: 32366391
[TBL] [Abstract][Full Text] [Related]
10. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
Gill J; Zhang W; Zhang Z; Roth M; Harrison DJ; Rowshan S; Erickson S; Gatto G; Kurmasheva R; Houghton P; Teicher B; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Oct; 67(10):e28606. PubMed ID: 32706456
[TBL] [Abstract][Full Text] [Related]
11. A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model.
Wu NF; Yamamoto J; Bouvet M; Hoffman RM
In Vivo; 2021; 35(1):105-109. PubMed ID: 33402455
[TBL] [Abstract][Full Text] [Related]
12. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
13. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
[TBL] [Abstract][Full Text] [Related]
15. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
[TBL] [Abstract][Full Text] [Related]
16. Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Wu NF; Samonte C; Wu J; Hozumi C; Obara K; Kubota Y; Aoki Y; Miyazaki J; Hoffman RM
In Vivo; 2022; 36(6):2598-2603. PubMed ID: 36309364
[TBL] [Abstract][Full Text] [Related]
17. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
[TBL] [Abstract][Full Text] [Related]
18. Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse Model.
Masaki N; Han Q; Samonte C; Wu NF; Hozumi C; Wu J; Obara K; Kubota Y; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2022 Nov; 42(11):5217-5222. PubMed ID: 36288875
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
